Trinity Biotech Shares Jump on 'Breakthrough' Results Trial of Glucose Monitoring Technology

MT Newswires Live

Jan 29, 2025

Trinity Biotech (TRIB) shares jumped 50% in recent Tuesday trading after the company said the latest pre-pivotal clinical trial for its continuous glucose monitoring technology yielded "breakthrough" results.

The modular device, described as "disruptively affordable and user-friendly," offers better signal quality and sensor performance, and a 25% to 30% enhancement in the key accuracy indicator compared with other previously released Waveform CGM sensors, the company said Tuesday in a statement.

The trial, which involved 30 diabetic participants, also showed that the patented device's low blood sugar reading accuracy achieved parity with industry benchmarks, the company said.

The company expects to complete further clinical trials for device enhancements and is scheduled to file for regulatory approval in the EU this year and in the US in 2026.

Price: 1.14, Change: +0.38, Percent Change: +50.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2507548851"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2507548851\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2507548851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-29 00:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507548851","market":"hk","top_or_hot":-1,"title":"Trinity Biotech Shares Jump on 'Breakthrough' Results Trial of Glucose Monitoring Technology","media":"MT Newswires Live","content":"<html><body><p> Trinity Biotech (TRIB) shares jumped 50% in recent Tuesday trading after the company said the latest pre-pivotal clinical trial for its continuous glucose monitoring technology yielded \"breakthrough\" results.</p><p>The modular device, described as \"disruptively affordable and user-friendly,\" offers better signal quality and sensor performance, and a 25% to 30% enhancement in the key accuracy indicator compared with other previously released Waveform CGM sensors, the company said Tuesday in a statement.</p><p>The trial, which involved 30 diabetic participants, also showed that the patented device's low blood sugar reading accuracy achieved parity with industry benchmarks, the company said.</p><p>The company expects to complete further clinical trials for device enhancements and is scheduled to file for regulatory approval in the EU this year and in the US in 2026.</p><p>Price: 1.14, Change: +0.38, Percent Change: +50.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trinity Biotech Shares Jump on 'Breakthrough' Results Trial of Glucose Monitoring Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrinity Biotech Shares Jump on 'Breakthrough' Results Trial of Glucose Monitoring Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-29 00:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Trinity Biotech (TRIB) shares jumped 50% in recent Tuesday trading after the company said the latest pre-pivotal clinical trial for its continuous glucose monitoring technology yielded \"breakthrough\" results.</p><p>The modular device, described as \"disruptively affordable and user-friendly,\" offers better signal quality and sensor performance, and a 25% to 30% enhancement in the key accuracy indicator compared with other previously released Waveform CGM sensors, the company said Tuesday in a statement.</p><p>The trial, which involved 30 diabetic participants, also showed that the patented device's low blood sugar reading accuracy achieved parity with industry benchmarks, the company said.</p><p>The company expects to complete further clinical trials for device enhancements and is scheduled to file for regulatory approval in the EU this year and in the US in 2026.</p><p>Price: 1.14, Change: +0.38, Percent Change: +50.13</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507548851","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507548851","pubTimestamp":1738080098,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Trinity Biotech  shares jumped 50% in recent Tuesday trading after the company said the latest pre-pivotal clinical trial for its continuous glucose monitoring technology yielded \"breakthrough\" results.The modular device, described as \"disruptively affordable and user-friendly,\" offers better signal quality and sensor performance, and a 25% to 30% enhancement in the key accuracy indicator compared with other previously released Waveform CGM sensors, the company said Tuesday in a statement.The trial, which involved 30 diabetic participants, also showed that the patented device's low blood sugar reading accuracy achieved parity with industry benchmarks, the company said.The company expects to complete further clinical trials for device enhancements and is scheduled to file for regulatory approval in the EU this year and in the US in 2026.Price: 1.14, Change: +0.38, Percent Change: +50.13","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","TRIB":"Trinity Biotech plc"},"translate_title":"Trinity Biotech股价因葡萄糖监测技术试验取得“突破性”结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRIB":0.9},"content_text":"Trinity Biotech (TRIB) shares jumped 50% in recent Tuesday trading after the company said the latest pre-pivotal clinical trial for its continuous glucose monitoring technology yielded \"breakthrough\" results.The modular device, described as \"disruptively affordable and user-friendly,\" offers better signal quality and sensor performance, and a 25% to 30% enhancement in the key accuracy indicator compared with other previously released Waveform CGM sensors, the company said Tuesday in a statement.The trial, which involved 30 diabetic participants, also showed that the patented device's low blood sugar reading accuracy achieved parity with industry benchmarks, the company said.The company expects to complete further clinical trials for device enhancements and is scheduled to file for regulatory approval in the EU this year and in the US in 2026.Price: 1.14, Change: +0.38, Percent Change: +50.13","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}